This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Academisch Ziekenhuis Leiden, Sanaria Inc., Stichting Katholieke Universteit. Active years: 2017-2018.
Company Filing History:
1 out of 47 
1 out of 26 
1 out of 1 Years Active: 2017-2018
Title: Chris J Janse: Innovator in Genetic Research
Introduction
Chris J Janse is a prominent inventor based in Leiden, Netherlands. He has made significant contributions to the field of genetic research, particularly in the development of genetically attenuated parasites. With a total of 2 patents, his work has the potential to impact vaccine development and pharmaceutical compositions.
Latest Patents
One of his latest patents is focused on the genetic attenuation of Plasmodium by B9 gene disruption. This patent discloses mutant-species parasites that are genetically attenuated (GAP). These parasites retain the ability to infect a host and invade host hepatocytes, but their development is completely arrested within the liver stage. Consequently, the parasites do not reach the blood stage of development. The patent also includes vaccines and pharmaceutical compositions comprising genetically attenuated sporozoites, as well as methods of using the same.
Career Highlights
Throughout his career, Chris has worked with notable organizations, including Sanaria Inc. His innovative research has positioned him as a key figure in the field of genetic research, particularly in the fight against malaria.
Collaborations
Chris has collaborated with esteemed colleagues such as Martijn W Vos and Takeshi Annoura. These partnerships have further enhanced his research and contributions to the scientific community.
Conclusion
Chris J Janse's work in genetic research, particularly in the development of genetically attenuated parasites, showcases his innovative spirit and dedication to advancing medical science. His contributions are paving the way for new approaches in vaccine development and treatment options.